COMPARISON
Exenatide vs Octreotide
6 attributes held for at least one of the two. 6 differ. Each value carries the register it came from and the date that register was read.
Answer
Exenatide is authorised or registered in 5 and Octreotide in 10 of the 10 registers read. Exenatide: highest phase Phase 2. Octreotide: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Exenatide | Octreotide | |
|---|---|---|
| Registered trials differs | 383 clinicaltrials.gov · 2026-10-03 | 344 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Byetta openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Octreotide Acetate openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Withdrawn ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | Not checked no record of "authorisedOn" for exenatide | 2025-06-30 ema · 2026-10-03 |
| EU withdrawn on differs | 2024-11-20 ema · 2026-10-03 | 2022-12-02 ema · 2026-10-03 |
| ATC code differs | A10BJ01 ema · 2026-10-03 | H01CB02 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Exenatide | placebo | Octreotide | placebo |
|---|---|---|---|---|
| Fatigue | 0.6% | 0.1% | 29.8% | 27.7% |
| Headache | 1.9% | 1.3% | - | - |
| Non-cardiac chest pain | 1.1% | 1.0% | - | - |
| Osteoarthritis | 0.9% | 1.0% | - | - |
| Dizziness | 0.8% | 0.4% | - | - |
| Constipation | 0.8% | 0.3% | - | - |
| Dyspepsia | 0.8% | 0.3% | - | - |
| Chronic obstructive pulmonary disease | 0.7% | 0.7% | - | - |
| Back pain | 0.5% | 0.6% | - | - |
| Sinusitis | 0.5% | 0.2% | - | - |
| Diarrhoea | - | - | 46.2% | 31.7% |
| Oedema peripheral | - | - | 34.9% | 19.6% |
| Asthenia | - | - | 33.3% | 20.9% |
| Nausea | - | - | 30.8% | 21.2% |
| Rash | - | - | 28.8% | 14.1% |
| Decreased appetite | - | - | 28.5% | 15.2% |
| Hypertension | - | - | 26.5% | 19.4% |
| Dyspnoea | - | - | 25.9% | 9.1% |
| Anaemia | - | - | 24.3% | 9.1% |
Trial register Exenatide: 24 placebo-controlled trials; Octreotide: 5. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Exenatide side effects · Octreotide side effects
LEGAL STATUS
Approval in each country read
| Country | Exenatide | Octreotide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Withdrawn | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Status unknown | Registered | TGA |
| Switzerland | Not on the register | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Not on the register | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.